Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis

Ju Sang Kim, Yong-Hyun Kim, Sang Haak Lee, Yee Hyung Kim, Jin-Woo Kim, Ji Young Kang, Sung Kyoung Kim, Seung Joon Kim, Yun-Seong Kang, Tae-Hyung Kim, Jeongha Mok, Min Kwang Byun, Hye Jung Park, Joon-Sung Joh, Yong Bum Park, Hyeong-Seok Lim, Hongjo Choi, Seung Heon Lee, Hyejin Kim, Jeongseong Yang, Hyunji Kim, Xianlin Shen, Abdullah Alsultan, InSook Cho, Lawrence Geiter, Tae Sun Shim, Ju Sang Kim, Yong-Hyun Kim, Sang Haak Lee, Yee Hyung Kim, Jin-Woo Kim, Ji Young Kang, Sung Kyoung Kim, Seung Joon Kim, Yun-Seong Kang, Tae-Hyung Kim, Jeongha Mok, Min Kwang Byun, Hye Jung Park, Joon-Sung Joh, Yong Bum Park, Hyeong-Seok Lim, Hongjo Choi, Seung Heon Lee, Hyejin Kim, Jeongseong Yang, Hyunji Kim, Xianlin Shen, Abdullah Alsultan, InSook Cho, Lawrence Geiter, Tae Sun Shim

Abstract

Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid has in vitro activity against Gram-positive bacteria, including Mycobacterium tuberculosis. This study evaluated the bactericidal activity, safety, and pharmacokinetics of delpazolid in patients with pulmonary tuberculosis (TB). Seventy-nine subjects, aged 19 to 75 years with newly diagnosed smear-positive TB with no prior treatment for the current episode and no confirmed resistance to rifampin or isoniazid, were randomized to receive delpazolid 800 mg once a day (QD), 400 mg twice a day (BID), 800 mg BID or 1,200 mg QD or an active control of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) or linezolid 600 mg BID. The primary endpoint was the average daily reduction in log transformed bacterial load, assessed on 7H11 solid-media culture, from days 0 to 14. The average daily decline in log-CFU was 0.044 ± 0.016, 0.053 ± 0.017, 0.043 ± 0.016, and 0.019 ± 0.017, for the delpazolid 800 mg QD, 400 mg BID, 800 mg BID, and the 1,200 mg QD groups, respectively. The average daily decline in log-CFU was 0.192 ± 0.028 for the HRZE group and 0.154 ± 0.023 for the linezolid 600 mg BID group. Three serious adverse events (SAE) were reported, one each in the delpazolid 400 mg BID group (death due to worsening of TB at day 2), the HRZE group (hospitalization due to pleural effusion) and the linezolid group (hyperkalemia); none of the SAEs were assessed as related to study drugs. This study has been registered at ClinicalTrials.gov with registration number NCT02836483.

Keywords: Mycobacterium tuberculosis; early bactericidal activity; experimental therapeutics; oxazolidinones.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Disposition of study subjects screened and randomized.
FIG 2
FIG 2
Results for each regimen group.

References

    1. World Health Organization. Global tuberculosis report 2019. WHO/CDS/TB/2019.15
    1. Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, van Deun A, Dat P-T, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID, STREAM Study Collaborators. 2019. A trial of a shorter regimen for rifampin resistant tuberculosis. N Engl J Med 380:1201–1213. 10.1056/NEJMoa1811867.
    1. World Health Organization. Target regimen profiles for TB treatment: candidates: rifampin-susceptible, rifampicin-resistant and pan-TB treatment regimens. WHO/HTM/TB/2016.16.
    1. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. 2003. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472–1477. 10.1164/rccm.200206-626OC.
    1. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. 2015. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomized trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385:1738–1747. 10.1016/S0140-6736(14)62002-X.
    1. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, Tuberculosis Trials Consortium. 2021. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 384:1705–1718. 10.1056/NEJMoa2033400.
    1. Tasneen R, Betoudji F, Tyagi S, Li S-Y, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. 2016. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 60:270–277. 10.1128/AAC.01691-15.
    1. U.S. Food and Drug Administration. Pretomanid tablets, for oral use Initial U.S. Approval: 2019 LIMITED POPULATION; Reference ID: 4477119,
    1. Jeong J-W, Jung S-J, Lee H-H, Kim Y-Z, Park T-K, Cho Y-L, Chae S-E, Baek S-Y, Woo S-H, Lee H-S, Kwak J-H. 2010. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother 54:5359–5362. 10.1128/AAC.00723-10.
    1. Agyeman AA, Ofori-Senso R. 2016. Efficacy and safety profile of linezolid in the treatment of multidrugresistant (MDR) and extensively drugresistant (XDR) tuberculosis: a systematic review and metaanalysis. Ann Clin Microbiol Anitmicrob 15:1–17. 10.1186/s12941-016-0156-y..
    1. Cho YL, Jang J. 2020. Development of delpazolid for the treatment of tuberculosis. Appl Sci 10:2211. 10.3390/app10072211.
    1. Cho Y-S, Lim H-S, Han S, Yoon SK, Kim H, Cho YL, Nam H-S, Bae K-S. 2019. Pharmacokinetics, pharmacodynamics, and tolerability of single -dose oral LCB01 -0371, a novel oxazolidinone with broad -spectrum activity, in healthy volunteers. Clin Ther 41:92–106. 10.1016/j.clinthera.2018.11.009.
    1. Cho YS, Lim HS, Lee SH, Cho YL, Nam HS, Bae KS. 2018. Multiple-dose safety, tolerability, pharmacokinetics, and pharmacodynamics of oral LCB01-0371 in healthy male volunteers. Clin Ther 40:2050–2064. 10.1016/j.clinthera.2018.10.007.
    1. Jung SW, Kim YK, Choi YW, Yu KS. 2018. Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic. Drug Design Dev Ther 12:1707–1714. 10.2147/DDDT.S155657..
    1. Douros A, Grabowski K, Stahlmann R. 2015. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 11:1849–1859. 10.1517/17425255.2015.1098617.
    1. Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM. 2020. Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis. Antimicrob Agents Chemother 64:e02012-19. 10.1128/AAC.02012-19.
    1. Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A. 2015. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. mBio 6:e01741-15–e01715. 10.1128/mBio.01741-15.
    1. Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Peloquin CA, Alsultan A, Thiel BA, Debanne SM, Boom WH, Diacon AH, Johnson JL. 2016. Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 60:6591–6599. 10.1128/AAC.01163-16.
    1. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. 2014. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 9:e94462. 10.1371/journal.pone.0094462.
    1. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuber Lung Dis 15:949–954. 10.5588/ijtld.10.0616.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit